The TCIA-HNSCC data further predicted that anti-CTLA-4 alone or in combination with anti-CTLA-4 and anti-PD-1 therapy may be more effective in low-risk group patients. The gene discussed is CTLA4; the disease is head and neck squamous cell carcinoma.